[Update on medical treatment of female stress urinary incontinence].
A reasonable assumption is that incontinence would be relieved by increasing urethral resistance through stimulating alpha-adrenergic receptors in urethral smooth muscle. A review of available medical treatment of stress urinary incontinence is done. Alpha-receptor agonists are not in common use because of systemic side-effects. Estrogens do not seem to have beneficial effect on stress urinary incontinence. Currently, new molecules such as duloxetine, are uptake inhibitor of serotonin and noradrenaline could provide a noninvasive therapy for patients with urinary incontinence. Further studies to identify clinical applications are required.
Yazbeck
C
C
Service de gynécologie-obstétrique, hôpital Bichat-Claude-Bernard, Paris, France. chayaz@cyberia.net.lb
Dhainaut
C
C
Batallan
A
A
Thoury
A
A
Madelenat
P
P
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000068736:Duloxetine Hydrochloride; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D009130:Muscle, Smooth / Q000187:drug effects / Q000503:physiopathology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014521:Urethra / Q000187:drug effects / Q000503:physiopathology; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000068736:Duloxetine Hydrochloride; D004967:Estrogens; D007099:Imipramine; D011942:Receptors, Adrenergic, alpha; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes